Neuregulin Allosteric Anti-HER3 Antibody 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
US2016319033 A1 2016-11-03 [US20160319033] / 2016-11-03
申请号/申请日
2013US-15035129 / 2013-11-07
发明人
CHARDES THIERRY;GABORIT NADEGE;LARBOURET CHRISTEL;PELEGRIN ANDRE;
申请人
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);INSTITUT REGIONAL DU CANCER DE MONTPELLIER;UNIVERSITE DE MONTPELLIER 2;
主分类号
IPC分类号
C07K-016/32G01N-033/574
摘要
(US20160319033) The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2013WO-IB02733 2013-11-07
主权利要求
(US20160319033) 1. An neuregulin noncompetitive allosteric anti-human-HER3 antibody comprising a heavy chain wherein a variable domain comprises: a H-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 2, a H-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 3, a H-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 4, a L-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 6, a L-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 7, a L-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 8, wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody specifically binds to HER3 with substantially the same affinity as an antibody comprising a heavy chain wherein the variable domain comprises SEQ ID NO: 2 for H-CDR1, SEQ ID NO: 3 for H-CDR2 and SEQ ID NO: 4 for H-CDR3 and a light chain wherein the variable domain comprises SEQ ID NO: 6 for L-CDR1, SEQ ID NO: 7 for L-CDR2 and SEQ ID NO: 8 for L-CDR3. 9. A nucleic acid sequence encoding i) a neuregulin noncompetitive allosteric anti-human-HER3 antibody comprising a heavy chain wherein a variable domain comprises: a H-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 2, a H-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 3, a H-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 4, a L-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 6, a L-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 7, and a L-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 8, wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody specifically binds to HER3 with substantially the same affinity as an antibody comprising a heavy chain wherein the variable domain comprises SEQ ID NO: 2 for H-CDR1, SEQ ID NO: 3 for H-CDR2 and SEQ ID NO: 4 for H-CDR3 and a light chain wherein the variable domain comprises SEQ ID NO: 6 for L-CDR1, SEQ ID NO: 7 for L-CDR2 and SEQ ID NO: 8 for L-CDR3, or ii) a fragment of the neuregulin noncompetitive allosteric anti-human-HER3 antibody. 12. A vector comprising a nucleic acid encoding i) a neuregulin noncompetitive allosteric anti-human-HER3 antibody comprising a heavy chain wherein a variable domain comprises: a H-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 2, a H-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 3, a H-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 4, a L-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 6, a L-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 7, and a L-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 8, wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody specifically binds to HER3 with substantially the same affinity as an antibody comprising a heavy chain wherein the variable domain comprises SEQ ID NO: 2 for H-CDR1, SEQ ID NO: 3 for H-CDR2 and SEQ ID NO: 4 for H-CDR3 and a light chain wherein the variable domain comprises SEQ ID NO: 6 for L-CDR1, SEQ ID NO: 7 for L-CDR2 and SEQ ID NO: 8 for L-CDR3, or ii) a fragment of the neuregulin noncompetitive allosteric anti-human-HER3 antibody, wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody is a monoclonal antibody. 13. A host cell comprising a. a nucleic acid encoding i) a neuregulin noncompetitive allosteric anti-human-HER3 antibody comprising a heavy chain wherein a variable domain comprises: a H-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 2, a H-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 3, a H-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 4, a L-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 6, a L-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 7, a L-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 8, wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody specifically binds to HER3 with substantially the same affinity as an antibody comprising a heavy chain wherein the variable domain comprises SEQ ID NO: 2 for H-CDR1, SEQ ID NO: 3 for H-CDR2 and SEQ ID NO: 4 for H-CDR3 and a light chain wherein the variable domain comprises SEQ ID NO: 6 for L-CDR1, SEQ ID NO: 7 for L-CDR2 and SEQ ID NO: 8 for L-CDR3, or ii) a fragment of the neuregulin noncompetitive allosteric anti-human-HER3 antibody, wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody is a monoclonal antibody; or b. a vector. comprising the nucleic acid. 14. A pharmaceutical composition comprising i) a neuregulin noncompetitive allosteric anti-human-HER3 antibody comprising a heavy chain wherein a variable domain comprises: a H-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 2, a H-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 3, a H-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 4, a L-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 6, a L-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 7, and a L-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 8, wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody specifically binds to HER3 with substantially the same affinity as an antibody comprising a heavy chain wherein the variable domain comprises SEQ ID NO: 2 for H-CDR1, SEQ ID NO: 3 for H-CDR2 and SEQ ID NO: 4 for H-CDR3 and a light chain wherein the variable domain comprises SEQ ID NO: 6 for L-CDR1, SEQ ID NO: 7 for L-CDR2 and SEQ ID NO: 8 for L-CDR3; or ii) a fragment of the neuregulin noncompetitive allosteric anti-human-HER3 antibody. 16. A method for treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of i) a neuregulin noncompetitive allosteric anti-human-HER3 antibody comprising a heavy chain wherein a variable domain comprises: a H-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 2, a H-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 3, a H-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 4, a L-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 6, a L-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 7, and a L-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 8; wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody specifically binds to HER3 with substantially the same affinity as an antibody comprising a heavy chain wherein the variable domain comprises SEQ ID NO: 2 for H-CDR1, SEQ ID NO: 3 for H-CDR2 and SEQ ID NO: 4 for H-CDR3 and a light chain wherein the variable domain comprises SEQ ID NO: 6 for L-CDR1, SEQ ID NO: 7 for L-CDR2 and SEQ ID NO: 8 for L-CDR3, or ii) a fragment of the neuregulin noncompetitive allosteric anti-human-HER3 antibody. 19. A method of diagnosing cancer, comprising contacting a biological sample of a subject with or likely to suffer from a cancer associated with HER3 expression with i) a neuregulin noncompetitive allosteric anti-human-HER3 antibody comprising a heavy chain wherein a variable domain comprises: a H-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 2, a H-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 3, a H-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 4, a L-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 6, a L-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 7, and a L-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 8; wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody specifically binds to HER3 with substantially the same affinity as an antibody comprising a heavy chain wherein the variable domain comprises SEQ ID NO: 2 for H-CDR1, SEQ ID NO: 3 for H-CDR2 and SEQ ID NO: 4 for H-CDR3 and a light chain wherein the variable domain comprises SEQ ID NO: 6 for L-CDR1, SEQ ID NO: 7 for L-CDR2 and SEQ ID NO: 8 for L-CDR3, or ii) a fragment thereof of the neuregulin noncompetitive allosteric anti-human-HER3 antibody, wherein said step of contacting is performed under conditions sufficient for the neuregulin noncompetitive allosteric anti-human-HER3 antibody or the fragment of the neuregulin noncompetitive allosteric anti-human-HER3 antibody to form complexes with cells of the biological sample that express HER3; and detecting and/or quantifying said complexes, whereby detection of said complexes is indicative of the presence of a cancer associated with HER3 expression in said subject.
法律状态
(US20160319033) LEGAL DETAILS FOR US2016319033  Actual or expected expiration date=2033-11-07    Legal state=ALIVE    Status=PENDING     Event publication date=2013-11-07  Event code=US/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=US US15035129  Application date=2013-11-07  Standardized application number=2013US-15035129     Event publication date=2013-11-07  Event code=US/EXMR  Event type=Administrative notifications  USPTO Examiner Name Primary Examiner: HALVORSON, MARK    Event publication date=2013-11-07  Event code=US/ART  Event type=Administrative notifications  USPTO Art Group  ART=1642     Event publication date=2013-11-07  Event code=US/DK  Event type=Examination events  Attorney Docket Number Docket Nbr: 13390018US Customer Nbr: 30743    Event publication date=2013-11-07  Event code=US/ENT  Event type=Administrative notifications  Business Entity Status: UNDISCOUNTED    Event publication date=2013-11-07  Event code=US/AIA  Event type=Administrative notifications  First Inventor File Indicated:  AIA=Yes     Event publication date=2016-05-06  Event code=US/PTARDY  Event indicator=Pos  Event type=Examination events  Patent Term Adjustment - Ready for Examination    Event publication date=2016-05-06  Event code=US/IDS  Event type=Examination events  Event type=OAI  Information Disclosure Statement Filed    Event publication date=2016-05-06  Event code=US/ENTYSTA  Event type=Administrative notifications  Entity Status Set to Undiscounted    Event publication date=2016-06-27  Event code=US/APPFILEREC  Event type=Administrative notifications  Event type=OAO  Filing Receipt    Event publication date=2016-07-26  Event code=US/DKNC  Event indicator=Pos  Event type=Examination events  Docketed New Case - Ready for Examination    Event publication date=2016-07-26  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner in GAU    Event publication date=2016-07-26  Event code=US/RECEIPTUP  Event type=Administrative notifications  Event type=OAO  Filing Receipt - Updated    Event publication date=2016-07-26  Event code=US/M903  Event indicator=Pos  Event type=Examination events  Event type=OAO  Notice of DO/EO Acceptance Mailed    Event publication date=2016-08-05  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment Owner: UNIVERSITE DE MONTPELLIER, FRANCE  Effective date of the event=2016-06-30  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNORS:CHARDES, THIERRY GABORIT, NADEGE LARBOURET, CHRISTEL ANDOTHERS REEL/FRAME:039349/0441     Event publication date=2016-08-05  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment Owner: INSTITUT REGIONAL DU CANCER DE MONTPELLIER, FRANCE  Effective date of the event=2016-06-30  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNORS:CHARDES, THIERRY GABORIT, NADEGE LARBOURET, CHRISTEL ANDOTHERS REEL/FRAME:039349/0441     Event publication date=2016-08-05  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment Owner: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC  Effective date of the event=2016-06-30  ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNORS:CHARDES, THIERRY GABORIT, NADEGE LARBOURET, CHRISTEL ANDOTHERS REEL/FRAME:039349/0441     Event publication date=2016-11-03  Event code=US/A1  Event type=Examination events  Application published  Publication country=US  Publication number=US2016319033  Publication stage Code=A1  Publication date=2016-11-03  Standardized publication number=US20160319033     Event publication date=2016-11-03  Event code=US/PGPUBN  Event indicator=Pos  Event type=Examination events  Event type=OAO  PG-Pub Issue Notification
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部